ライフサイエンスコーパス: chloroquine

1 smodium parasite with no cross-resistance to chloroquine.

2 combination therapies or to reinstate use of chloroquine.

3 wing alkalinization of the phagolysosomes by chloroquine.

4 r cheek injection of capsaicin, formalin, or chloroquine.

5 ared to 17% when treated in combination with chloroquine.

6 1040, 1494, and 1585 nmol/L for double-dose chloroquine.

7 te's accumulation of, and susceptibility to, chloroquine.

8 0% versus 16% when given in combination with chloroquine.

9 amodiaquine and the former first-line agent chloroquine.

10 lution and virologic clearance benefits with chloroquine.

11 thesis, and folate metabolism in response to chloroquine.

12 Two studies assessed the efficacy of chloroquine; 1 trial, which compared higher-dose (600 mg

13 ith a macrolide (23.8%; 1.447, 1.368-1.531), chloroquine (16.4%; 1.365, 1.218-1.531), and chloroquine

14 en artesunate-mefloquine than in those given chloroquine (18.0 h [range 6.0-48.0] vs 24.0 h [6.0-60.0

15 Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, an

16 and-Myanmar border were randomized to either chloroquine (25mg base/kg) or dihydroartemisinin-piperaq

17 were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide,

18 with a macrolide (8.1%; 5.106, 4.106-5.983), chloroquine (4.3%; 3.561, 2.760-4.596), and chloroquine

19 harmacological inhibition of autophagy using Chloroquine (50 mg kg(-1) day(-1) ) abolishes the benefi

20 of hematin crystallization and inhibition by chloroquine, a common quinoline antimalarial drug.

21 ning it with the FDA-approved anti-malarial, chloroquine, a known lysosomotropic compound, which impr

22 Pharmacological intervention using chloroquine, a lysosomal inhibitor, decreased lysosomal

23 sensitive to the antiproliferative effect of chloroquine, a lysosomotropic agent often used as a phar

24 ce of impaired autophagosome clearance after chloroquine administration in these mice indicative of i

25 ssfully treated with the autophagy inhibitor chloroquine after failure of the BRAF(V600E) inhibitor v

26 re included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxy

27 ne plus primaquine, compared with receipt of chloroquine alone.

28 LMP-inducing agent chloroquine also displayed a synergistic anticancer effe

29 stemic mouse infection model, treatment with chloroquine also reduced SCVs.

30 or inhibiting autophagy pharmacologically by chloroquine, also induced the expression of CCL5 in mela

31 Plasmodium falciparum parasites resistant to chloroquine, amodiaquine, or piperaquine harbor mutation

32 Chloroquine - an approved malaria drug - is known in nan

33 In vitro and in vivo administration of chloroquine, an endo/lysosomal inhibitor, mimicked Pepst

34 Chloroquine, an inhibitor of lysosomal degradation, did

35 s of bioactive quinoline derivatives such as chloroquine analogues.

36 id (FA) oxidation that was inhibited by both chloroquine and 3-methyl adenine, consistent with traffi

37 mpacted H2O2 levels in mitochondria, whereas chloroquine and a glucose-6-phosphate dehydrogenase (G6P

38 compare prescriptions for hydroxychloroquine/chloroquine and azithromycin in February to April 2020 v

39 Moreover, we evaluated chloroquine and chlorpromazine in vivo using mouse-adapt

40 Moreover, we evaluated two of these, chloroquine and chlorpromazine, in vivo using a mouse-ad

41 they displayed synergistic interactions with chloroquine and dihydroartemisinin against parasite.

42 Chloroquine and dihydroartemisinin-piperaquine are both

43 ingly, we found that the autophagy inhibitor chloroquine and genetic or pharmacologic inhibition of s

44 Nicholas White and coauthors discuss chloroquine and hydroxychloroquine pharmacology in the c

45 ritonavir, interferon beta, corticosteroids, chloroquine and hydroxychloroquine, and ivermectin) unde

46 sites comparable to the known antimalarials, chloroquine and mefloquine.

47 hat substituting Ser-33 with alanine reduced chloroquine and quinine resistance by ~50% compared with

48 Chloroquine and rapamycin, an inhibitor and an activator

49 e analyze gene expression changes induced by chloroquine and show that this antimalarial drug efficie

50 parasites also have increased sensitivity to chloroquine and some other quinoline antimalarials, but

51 ur analysis predicts that the combination of chloroquine and sulfadoxine-pyrimethamine or fosmidomyci

52 in haplotypes known to confer resistance to chloroquine and sulfadoxine-pyrimethamine.

53 pathic side-effects of the anti-malaria drug chloroquine and the antibiotic gentamicin.

54 on); all patients received a 3-day course of chloroquine and were followed for 180 days.

55 sitive to the antimalarial drugs artesunate, chloroquine, and atovaquone, resulting in accelerated pa

56 Histamine, chloroquine, and capsaicin intradermally elicited simila

57 s-positive neurons elicited by id histamine, chloroquine, and capsaicin, respectively, 3.7%, 4.3%, an

58 ositive following id injection of histamine, chloroquine, and capsaicin, respectively.

59 ine (SP), SP+amodiaquine, SP+piperaquine, SP+chloroquine, and co-trimoxazole.

60 s, chlorpromazine, methyl-beta-cyclodextrin, chloroquine, and concanamycin A dramatically reduced SHF

61 ral footprinting data show that amodiaquine, chloroquine, and cytosporone B bind the Nurr1 LBD; ligan

62 e to the former first-line antimalarial drug chloroquine, and it modulates the responsiveness to a wi

63 ic use of many antimalarial drugs, including chloroquine, and limited our ability to treat malaria ac

64 nction by temperature blockade, brefeldin A, chloroquine, and multiple inhibitors that blocked produc

65 , including artemisinin combination therapy, chloroquine, and sulfadoxine-pyrimethamine.

66 Drug control subjects received primaquine, chloroquine, and uninfected mosquito bites.

67 esting that the antiproliferative effects of chloroquine are independent of its suppressive actions o

68 Hydroxychloroquine and chloroquine are used extensively in malaria and rheumato

69 lenge, compared to infectivity controls, 3/3 chloroquine arm subjects displayed delayed patent parasi

70 lenge, compared to infectivity controls, 3/3 chloroquine arm subjects displayed delayed patent parasi

71 2-15 P. falciparum-infected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some recei

72 2-15 P. falciparum-infected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some recei

73 -negative while only one subject (primaquine/chloroquine arm) remained PCR-negative.

74 r negative, while only 1 subject (primaquine/chloroquine arm) remained polymerase chain reaction-nega

75 ed post-exposure primaquine (CVac-primaquine/chloroquine arm).

76 ved postexposure primaquine (CVac-primaquine/chloroquine arm).

77 The novel use of chloroquine as a macrophage-preconditioning agent presen

78 umors from mice treated with penfluridol and chloroquine as compared to penfluridol alone.

79 luated CVac regimens using primaquine and/or chloroquine as the partner drug to discern whether blood

80 to <=60 years old to evaluate the effects of chloroquine, atovaquone/proguanil (Malarone), and doxycy

81 Inhibiting autophagy by chloroquine, bafilomycin, 3-methyladenine or LC3BsiRNA,

82 Cotreatment with the autophagy inhibitor chloroquine blocked the decrease in human ataxin-3 level

83 ced the ability of this protein to transport chloroquine by approximately 93 and 82%, respectively, w

84 Chloroquine can impair the immune responses to intraderm

85 ntradermal (id) microinjection of histamine, chloroquine, capsaicin, or vehicle into the left cheek.

86 etrial cells, a phenotypical bitter tastant (chloroquine, ChQ) reverses the rise in intracellular Ca(

87 ine-resistant parasites and propose targeted chloroquine combination therapies.

88 We identified potential drug targets for chloroquine combination therapies.

89 e, but not alpha-methyl-5-hydroxytryptamine, chloroquine, compound 48/80, or bile acid, was markedly

90 On human lung parenchymal explants, chloroquine concentration clinically achievable in the l

91 to determine the in vivo efficacy of higher chloroquine concentrations against P. falciparum with re

92 In parallel, median chloroquine concentrations were 471, 688, and 809 nmol/L

93 ce-conferring genotype (pfcrt 76T) and day 7 chloroquine concentrations were determined.

94 ht on the function of PfCRT and suggest that chloroquine could be reevaluated as an antimalarial drug

95 h Plasmodium chabaudi by mosquito bite under chloroquine cover does not generate pre-erythrocytic imm

96 Plasmodium vivax malaria has long relied on chloroquine (CQ) against blood-stage parasites plus prim

97 ABSTRACT: Chloroquine (CQ) and histamine are pruritogens commonly

98 Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the

99 Chloroquine (CQ) and hydroxychloroquine (HCQ) are used t

100 Although the lysomotropic drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been

101 hthalmology recommendations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopath

102 g the treatment effects of the antimalarials chloroquine (CQ) and quinacrine (Q) on KRAS mutant lung

103 ptosis, while the inhibition of autophagy by chloroquine (CQ) enhanced palmitic acid-induced apoptosi

104 emonstrate that the common anti-malaria drug chloroquine (CQ) extends the lifespan of ZIKV-infected i

105 Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although t

106 r over a half-century the anti-malarial drug chloroquine (CQ) has been used as a therapeutic agent, a

107 gregate number, but a 72 h co-treatment with chloroquine (CQ) in GFP-72Q-expressing HEK293 cells incr

108 Chloroquine (CQ) is a widely used antimalarial drug with

109 lled and randomly assigned to receive either chloroquine (CQ) or artemether-lumefantrine (AL), alone

110 studies have investigated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in

111 hey demonstrated that autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced th

112 dence of the development of Plasmodium vivax chloroquine (CQ) resistance, there have been no trials c

113 KEY POINTS: Chloroquine (CQ) stimulates itch nerves and causes inten

114 Wild-type PfCRT (PfCRT3D7) lacks significant chloroquine (CQ) transport activity, but the introductio

115 decades, treatment of malaria has relied on chloroquine (CQ), a safe and affordable 4-aminoquinoline

116 higher potency of autophagy inhibition than chloroquine (CQ), a well-known autophagy inhibitor that

117 droxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease.

118 st-line malaria drugs, artemisinin (ART) and chloroquine (CQ), lowering the IC(50) values of ART and

119 skin-nerve preparation was used to evaluate chloroquine (CQ)- and histamine-induced activation of af

120 target of rapamycin) pathway inhibitors and chloroquine (CQ)-an anti-malarial drug used as a cancer

121 Chloroquine (CQ)-resistant Plasmodium vivax is increasin

122 oline-derived antimalarial family, including chloroquine (CQ).

123 P. vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone

124 nfected patients were treated radically with chloroquine (CQ; 25 mg/kg over 3 days) and primaquine (P

125 lled trial of blood- plus liver-stage drugs (chloroquine [CQ], 3 d; artemether-lumefantrine [AL], 3 d

126 utophagy inhibitors bafilomycin A1 (Baf) and chloroquine demonstrate that autophagy is required for A

127 s, pharmacological autophagy inhibition with chloroquine derivatives depletes cells with high CD44 ex

128 Unlike previous studies, CVac-chloroquine did not produce sterile immunity.

129 We found that chloroquine diphosphate (CLQ), an antimalarial drug, inh

130 AG is modulated in an opposing manner during chloroquine-evoked scratching.

131 laria-naive, healthy adult volunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine a

132 or twice daily, with patients not receiving chloroquine found minor fever resolution and virologic c

133 A 2-muM concentration of chloroquine fully arrests layer generation and step adva

134 (mean 11.5 h [95% CI 8.3-14.6]) than in the chloroquine group (14.8 h [11.7-17.8]; p=0.034).

135 62%; 95% CI 52.2-70.6]) than in those in the chloroquine group (83 [75%; 65.6-82.5]; p=0.035).

136 rsus 61 (55% [45-64]) of 111 patients in the chloroquine group (difference in proportion 29% [95% CI

137 up versus 2828 days per 1000 patients in the chloroquine group (incidence rate ratio 0.858 [95% CI 0.

138 ine group and 41 (84%) of 49 patients in the chloroquine group at baseline, and in three (6%) of 49 p

139 eat malaria, the prevalence of resistance to chloroquine has decreased.

140 Hydroxychloroquine and chloroquine have antiviral effects in vitro against seve

141 Hydroxychloroquine and chloroquine have been proposed as treatments for coronav

142 -mediated conditions, hydroxychloroquine and chloroquine, have recently attracted widespread interest

143 el of pruritogens (C48/80, endothelin, 5-HT, chloroquine, histamine, lysophosphatidic acid, trypsin,

144 but a significant reduction in those taking chloroquine; however, accepted antibody levels were achi

145 Although chloroquine, hydroxychloroquine, and quinine are used fo

146 did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versu

147 versus those treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6+/

148 ll studies have shown a potential benefit of chloroquine/hydroxychloroquine+/-azithromycin for the tr

149 Hospitalized patients treated with chloroquine/hydroxychloroquine+/-azithromycin from March

150 s disease 2019 patients to date treated with chloroquine/hydroxychloroquine+/-azithromycin, no instan

151 re treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine.

152 ugs and natural compounds such as melatonin, chloroquine, imiquimod, resveratrol, piceatannol, querce

153 dose and 66%, 84%, and 91% after double-dose chloroquine in children aged <5, 5-9, and 10-14 years, r

154 mode of action of a bromo analog of the drug chloroquine in rapidly frozen Plasmodium falciparum-infe

155 d AO affect the accumulation and activity of chloroquine in these parasites.

156 pe that was mimicked by the fusion inhibitor chloroquine in wild-type cells and rescued by expression

157 an autophagosome-lysosome fusion inhibitor, chloroquine, indicating that Rab27b KD induces a defect

158 xis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plas

159 xis vaccination with sporozoites (CVac) with chloroquine induces protection against homologous P. fal

160 Surprisingly, chloroquine inhibits calcium flux induced by RNA-contain

161 Further studies reveal that chloroquine inhibits hematin crystallization by binding

162 uggesting that this lesser known function of chloroquine is involved in the neutrophil activation ind

163 ecause concentrations increase with age when chloroquine is prescribed according to body weight.

164 CVac-primaquine/chloroquine is safe and induces sterile immunity to P. f

165 CVac-primaquine/chloroquine is safe and induces sterile immunity to P. f

166 lkalinization of the acidic environment with chloroquine led to a rapid increase in the number of S.

167 G-protein-coupled receptor C11 agonist), and chloroquine (mas-related G-protein-coupled receptor A3 a

168 Of note, chloroquine-mediated blockade of autophagy increased acc

169 Besides its antiviral activity, chloroquine might also mitigate the cytokine storm assoc

170 offers significant advantages compared with chloroquine monotherapy and supports a unified treatment

171 eive either artesunate-mefloquine (n=127) or chloroquine (n=125); 226 (90%) patients comprised the mo

172 an that of control cells, and treatment with chloroquine normalized the pH.

173 Hydroxychloroquine or chloroquine, often in combination with a second-generati

174 PK inhibitor compound C, lysosomal inhibitor chloroquine or autophagy inhibitor 3MA enhanced gemcitab

175 inistration of autophagic inhibitors such as chloroquine or bafilomycin A1, or depletion of autophagy

176 activity) were randomised to receive 3 d of chloroquine or dihydroartemisinin-piperaquine in combina

177 ine regimens (total dose 7mg/kg) with either chloroquine or dihydroartemisinin-piperaquine.

178 gnaling through the endosome is inhibited by chloroquine or dynasore.

179 ecently all come to the same conclusion-that chloroquine or hydroxchloroquine are unlikely to provide

180 gy in the tumor cells as well as whether the chloroquine or hydroxychloroquine actually inhibit the a

181 noculated by mosquitoes to volunteers taking chloroquine or mefloquine (chemoprophylaxis with sporozo

182 Here, we evaluate CVac regimens using chloroquine or primaquine as the partner drug to discern

183 e for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low

184 ation of these drugs in patients with severe chloroquine or quinine poisoning.

185 t mite or aerosol ova-albumin challenge, and chloroquine or quinine were tested in both prophylactic

186 torial activity between a Chk1 inhibitor and chloroquine or the LDHA/LDHB inhibitor GSK 2837808A.

187 2% were Fos-positive following id histamine, chloroquine, or capsaicin.

188 injection of various pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous s

189 ed French patients who had taken intentional chloroquine overdoses, of whom 33 died (11%), and 16 hea

190 that compared adults with COVID-19 receiving chloroquine phosphate, 500 mg once or twice daily, with

191 ax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100,

192 of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of ch

193 ergistic growth inhibition when treated with chloroquine plus the tyrosine kinase inhibitors erlotini

194 The autophagy inhibitor chloroquine potentiated the antitumor effects of 9-ING-4

195 or example, the weak-base anti-malarial drug chloroquine prevents exogenous Tat degradation and enhan

196 cytokines, and inhibition of autophagy with chloroquine prevents the ability of IL-6 to protect from

197 c signatures were also found for atovaquone, chloroquine, proguanil, cycloguanil and methylene blue.

198 live Pf sporozoites (PfSPZ Challenge) under chloroquine prophylaxis (PfSPZ-CVac), and were protected

199 ria-naive adults, all CVac subjects received chloroquine prophylaxis and bites from 12-15 P. falcipar

200 ria-naive adults, all CVac subjects received chloroquine prophylaxis and bites from 12-15 P. falcipar

201 48/80, endothelin-1), not non-histaminergic (chloroquine) pruritogens in Trpv4 keratinocyte-specific

202 id could partially reconstitute the level of chloroquine/quinine resistance.

203 , and was blocked by the lysosomal inhibitor chloroquine, rather than proteasome inhibitor MG-132.

204 ide, bafilomycin A1, or the antimalaria drug chloroquine reduced SCVs in infected host cells.

205 drug resistance-associated loci such as the chloroquine related crt and sulfadoxine-pyrimethamine re

206 -Bissau, routinely used triple standard-dose chloroquine remained effective for decades despite the e

207 Understanding the basis of P. vivax chloroquine resistance (CQR) will inform drug discovery

208 cted with P. falciparum genotypes conferring chloroquine resistance (n = 195, P < .001).

209 micin protection assay in combination with a chloroquine resistance assay to quantify total and cytos

210 udies will explore the use of these drugs as chloroquine resistance blockers.

211 Fortunately, chloroquine resistance comes at a fitness cost to the pa

212 Chloroquine resistance is dose dependent and can be over

213 pe PfCRT and a PfCRT variant associated with chloroquine resistance transport both ferrous and ferric

214 rtain mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) alter the par

215 n drug resistance determinants P. falciparum chloroquine resistance transporter (PfCRT) and multidrug

216 we present the argument that the parasite's chloroquine resistance transporter (PfCRT) constitutes a

217 The Plasmodium falciparum chloroquine resistance transporter (PfCRT) is a key cont

218 aquine harbor mutations in the P. falciparum chloroquine resistance transporter (PfCRT), a transporte

219 The chloroquine resistance transporter of the human malaria

220 The chloroquine resistance transporter PfCRT of the human ma

221 s expressing an Asian/African variant of the chloroquine resistance transporter PfCRT.

222 iously generated for the malaria parasite's 'chloroquine resistance transporter' (PfCRT).

223 r2 (multidrug resistance protein 2) and crt (chloroquine resistance transporter) also showed strong a

224 nce of selection in a region upstream of the chloroquine resistance transporter, a putative chloroqui

225 n within the gene encoding the P. falciparum chloroquine resistance transporter, PfCRT.

226 Chloroquine resistance-conferring isoforms of PfCRT redu

227 s protein was saturable and inhibited by the chloroquine resistance-reverser verapamil.

228 lasmodium vivax malaria in areas of emerging chloroquine resistance.

229 loroquine resistance transporter, a putative chloroquine-resistance determinant.

230 stance haplotypes, and all clusters shared a chloroquine-resistance genotype matching the pfcrt haplo

231 In chloroquine-resistant (but not chloroquine-sensitive) pa

232 nst cultured chloroquine-sensitive (3D7) and chloroquine-resistant (W2) strains of P. falciparum.

233 smodial activities of QC, MB, and AO against chloroquine-resistant and chloroquine-sensitive P. falci

234 lation at Ser-33 and Ser-411 of PfCRT of the chloroquine-resistant P. falciparum strain Dd2 and show

235 Thus, we identified metabolic weaknesses of chloroquine-resistant parasites and propose targeted chl

236 tment, we compared transcriptomics data from chloroquine-resistant parasites in the presence or absen

237 r fosmidomycin may be more effective against chloroquine-resistant parasites than either drug alone;

238 hinol B shows similarly high potency against chloroquine-resistant Plasmodium falciparum.

239 uction of the C101F or L272F mutation into a chloroquine-resistant variant of PfCRT reduced the abili

240 ective for decades despite the existence of "chloroquine-resistant" P. falciparum.

241 In vivo, chloroquine restored locomotion, rescued average cross-s

242 iversity of Ottawa for hydroxychloroquine or chloroquine retinopathy screening during 2011-2014 under

243 acquired by the PfCRT variant as a result of chloroquine selection.

244 ependently highly predictive of mortality in chloroquine self-poisoning.

245 a TLR7/8 dependent mechanism; this leads to chloroquine sensitive production of pro-inflammatory cyt

246 ipain 2 and falcipain 3 and against cultured chloroquine-sensitive (3D7) and chloroquine-resistant (W

247 reased lipophilicity and were potent against chloroquine-sensitive (NF54) and -resistant (Dd2 and 7G8

248 y active against intraerythrocytic stages of chloroquine-sensitive and resistant Plasmodium falciparu

249 MB, and AO against chloroquine-resistant and chloroquine-sensitive P. falciparum and determined wheth

250 In chloroquine-resistant (but not chloroquine-sensitive) parasites, AO and QC increased th

251 logues were further assessed in asexual 3D7 (chloroquine-sensitive) strains of P. falciparum parasite

252 d 16 healthy volunteers who took 620 mg base chloroquine single doses.

253 elivery in a trial comparing SPAZ to SP plus chloroquine (SPCQ).

254 find that the heme-binding antimalarial drug chloroquine specifically increases labile cytosolic heme

255 ed with artemether-lumefantrine (Study 1) or chloroquine (Study 2).

256 ot sterile protection, while 3/11 primaquine/chloroquine subjects remained blood smear negative.

257 ot sterile protection, while 3/11 primaquine/chloroquine subjects remained blood-smear negative.

258 t of mice with a clinically relevant dose of chloroquine substantially decreased the accumulation of

259 sms of action, and categories of resistance: chloroquine, sulfadoxine-pyrimethamine, artemisinin, and

260 Chloroquine suppresses and clears blood-stage parasitemi

261 Chloroquine suppresses and clears blood-stage parasitemi

262 contrast to the rapid and complete return of chloroquine-susceptible falciparum malaria after chloroq

263 either genetically or pharmacologically with chloroquine, synergizes with dual ICB therapy (anti-PD1

264 mg/kg artesunate and 25 mg/kg mefloquine) or chloroquine (target dose 25 mg/kg).

265 Addition of chloroquine that suppressed autophagic flux to 2D GBM cu

266 c analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine).

267 aimed to compare artesunate-mefloquine with chloroquine to define the optimum treatment for uncompli

268 epatotoxicity, effects that were reversed by chloroquine to disrupt autophagy.

269 its and harms of using hydroxychloroquine or chloroquine to treat COVID-19 is very weak and conflicti

270 -standing, yet with greatly decreased use of chloroquine to treat malaria, the prevalence of resistan

271 The widespread use of chloroquine to treat Plasmodium falciparum infections ha

272 epigenetically the cellular acetylome, with chloroquine, to alter the lysosomal environment to favor

273 All patients received a 3-day course of chloroquine (total dose of 1500 mg).

274 ed the definition for hydroxychloroquine and chloroquine toxicity provided by the 2016 American Acade

275 analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxici

276 We further show that iron and chloroquine transport via PfCRT is electrogenic.

277 f several genes of P. falciparum involved in chloroquine transport, apicoplast biogenesis, and phosph

278 Alcohol reduced autophagy flux in vivo in chloroquine-treated mice as well as in vitro in hepatocy

279 se in plasma levels of FABP4 is inhibited by chloroquine treatment of mice.

280 To understand biological changes induced by chloroquine treatment, we compared transcriptomics data

281 thione generation and lipid synthesis during chloroquine treatment.

282 sed autophagy, effects that were reversed by chloroquine treatment.

283 rtic VEGFA that could be blocked by systemic chloroquine treatment.

284 rabies antibody geometric mean titer in the chloroquine versus control groups 28 days after vaccinat

285 stance had favorable clinical responses when chloroquine was added to vemurafenib.

286 Standard or double-dose chloroquine was given to 892 children aged <15 years wit

287 served effect of combination trametinib plus chloroquine was not restricted to PDA as other tumors, i

288 This effect of chloroquine was not seen in the absence of intact Tet38

289 , the clinically approved antimalarial agent chloroquine was shown to reduce nanoparticle uptake in m

290 that treatment with the antiautophagic drug chloroquine was sufficient to up-regulate MBNL1 and 2 pr

291 Chloroquine was used for malaria treatment until resista

292 roquine-susceptible falciparum malaria after chloroquine was withdrawn from Malawi, a reemergence of

293 After chloroquine washout, subjects, including treatment-naive

294 After a chloroquine washout, subjects, including treatment-naive

295 o confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-

296 chloroquine (16.4%; 1.365, 1.218-1.531), and chloroquine with a macrolide (22.2%; 1.368, 1.273-1.469)

297 chloroquine (4.3%; 3.561, 2.760-4.596), and chloroquine with a macrolide (6.5%; 4.011, 3.344-4.812)

298 ps (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychlor

299 of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone,

300 analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of